Agents targeting tyrosine kinase activity have an excellent therapeutic index, effectively targeting constitutively activated bcr-abl in CML and KIT in gastrointestinal stromal tumors (GIST) [24], [25], [26], with minimal toxicity compared to cytotoxic therapies [27]. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.